Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Hematologists who Treat Lymphoma

Articles with lock require a subscription to GLG News | Request a free trial
August 6, 2008
Boy will this p.... off Urologists as well as AARP!
Analysis of: Panel Urges End to Prostate Screening at Age 75 | www.nytimes.com
Author: GLG Expert Contributor
Since treatment may be worse than the disease it is being recommended that routine prostate cancer screening be stopped after the age of 75.
July 31, 2008
Amgen and J & J: Not hurt as much as we had predicted.
Analysis of: Amgen Told to Reword Drug Label | www.nytimes.com
Author: GLG Expert Contributor
Amgens Aranesp sales fell 26% and J & J's Procrit sales fell 23%."Yaron Werber, a biotechnology analyst at Citi Investment Research, estimated that the new label could reduce the use of Aranesp for cancer patients in this country — the drug is also used by people with kidney disease — by an additional...
July 31, 2008
Lung Cancer Screening: Here we go again.
Analysis of: Corrections Weaken Cancer Study | online.wsj.com
Author: GLG Expert Contributor
Lung cancer screening does not appear to prevent death at least in this study.
July 30, 2008
Avastin may not get approval of "cost-conscious" EMEA
Analysis of: Roche Files Avastin for Wider Label in EU | www.therapeuticsdaily.com
Author: GLG Expert Contributor
Avastin ( Roche/Genentech) extended time to progression when combined with Docotaxel ( Sanofi-Aventis) in patients with metastatic breast cancer as compared to Docotaxel alone, but did not prolong survival. Unlike approval by the FDA,the EMEA is more cost conscious and may be reluctant to...
July 29, 2008
Avastin use in breast ca in the EU? No surprise but does it prolong survival?? Who is the winner??
Analysis of: Roche Files Avastin for Wider Label in EU | www.therapeuticsdaily.com
Author: GLG Expert Contributor
"The filing is supported by data from the phase III Avado trial, which investigated Avastin in combination with docetaxel compared wwith docetaxel alone in the first-line treatment of patients with metastatic breast cancer, Roche said in a statement."
July 28, 2008
Doctors and cancer medications: the pressure should be shifted to health plans
Analysis of: Pricey Drugs Put Squeeze on Doctors | online.wsj.com
Author: GLG Expert Contributor
Doctors can not remain in the middle between pharmaceutical companies and insurance and health plans. Reimbursement for oreal and IV drugs should be comparable , in order to avoid over-prescription of IV drugs , even if they are not as efficacious or more toxic. The patient's helath plan ( the government...
July 28, 2008
Lilly is replacing oine of its compounds with another in a subset of NSCLC
Analysis of: Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
Pemetrexed (lilly) with Cisplatinum is less toxic and may be more efficacious in a subset of patients with advanced NSCLC than Gemcitibine ( another Lilly compound) /Cisplatin combination. he real question is how this comapres to Avastin ( Genentech) or even the antibody Cetuximab ( Imclone) in...
July 28, 2008
OLD news, but positive results and higher visibility will definitely benefit Bayer
Analysis of: Sorafenib in Advanced Hepatocellular Carcinoma | content.nejm.org
Author: GLG Expert Contributor
The New England Journal of Medicine report confirms that Bayer/Onyx Nexavar prolongs median survival and time to progression in patients with advanced HCC. This trumor is a world wide health problem, so such positive news, although old, in a reputable journal, will lead to wider use of this oral...
July 28, 2008
Erbitux may add to chemotherapy in a subset of NSCLC patients
Analysis of: Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy | jco.ascopubs.org
Author: GLG Expert Contributor
In a US multicenter Phase II study, Erbitux ( Imclone) added to efficacy of Carboplatinum and Palcitaxel in a subset of NSCLC patients whose tumors had extra copies of EGFR that is targeted by Cetuxiamb. FISH techniques still has problems with standardization and larger number of patients are needed...
July 24, 2008
Sorafenib (Bayer) in hepatocellular carcinoma (HCC): already factored in!
Analysis of: Sorafenib in Advanced Hepatocellular Carcinoma | content.nejm.org
Author: GLG Expert Contributor
Sorafenib increases time to progression and median survival in HCC. (World wide a major neoplasm)

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next51 to 60 of 680

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T13:45:22.747